|
1
|
Boyle P and Langman JS: ABC of colorectal
cancer: Epidemiology. BMJ. 321:805–808. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Haggar FA and Boushey RP: Colorectal
cancer epidemiology: Incidence, mortality, survival, and risk
factors. Clin Colon Rectal Surg. 22:191–197. 2009. View Article : Google Scholar :
|
|
3
|
Carmeliet P and Jain RK: Angiogenesis in
cancer and other diseases. Nature. 407:249–257. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Scaldaferri F, Vetrano S, Sans M, Arena V,
Straface G, Stigliano E, Repici A, Sturm A, Malesci A, Panes J, et
al: VEGF-A links angiogenesis and inflammation in inflammatory
bowel disease pathogenesis. Gastroenterology. 136:585–595.e585.
2009. View Article : Google Scholar
|
|
5
|
Ambs S, Merriam WG, Bennett WP,
Felley-Bosco E, Ogunfusika MO, Oser SM, Klein S, Shields PG,
Billiar TR and Harris CC: Frequent nitric oxide synthase-2
expression in human colon adenomas: Implication for tumor
angiogenesis and colon cancer progression. Cancer Res. 58:334–341.
1998.PubMed/NCBI
|
|
6
|
Lala PK and Chakraborty C: Role of nitric
oxide in carcinogenesis and tumour progression. Lancet Oncol.
2:149–156. 2001. View Article : Google Scholar
|
|
7
|
Karar J and Maity A: PI3K/AKT/mTOR pathway
in angiogenesis. Front Mol Neurosci. 4:512011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pratheeshkumar P, Sreekala C, Zhang Z,
Budhraja A, Ding S, Son YO, Wang X, Hitron A, Hyun-Jung K, Wang L,
et al: Cancer prevention with promising natural products:
Mechanisms of action and molecular targets. Anticancer Agents Med
Chem. 12:1159–1184. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gee E, Milkiewicz M and Haas TL: p38 MAPK
activity is stimulated by vascular endothelial growth factor
receptor 2 activation and is essential for shear stress-induced
angiogenesis. J Cell Physiol. 222:120–126. 2010. View Article : Google Scholar
|
|
10
|
Olsson AK, Dimberg A, Kreuger J and
Claesson-Welsh L: VEGF receptor signalling - in control of vascular
function. Nat Rev Mol Cell Biol. 7:359–371. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cianchi F, Cortesini C, Fantappiè O,
Messerini L, Schiavone N, Vannacci A, Nistri S, Sardi I, Baroni G,
Marzocca C, et al: Inducible nitric oxide synthase expression in
human colorectal cancer: Correlation with tumor angiogenesis. Am J
Pathol. 162:793–801. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Reinacher-Schick A, Pohl M and Schmiegel
W: Drug insight: Antiangiogenic therapies for gastrointestinal
cancers - focus on monoclonal antibodies. Nat Clin Pract
Gastroenterol Hepatol. 5:250–267. 2008. View Article : Google Scholar
|
|
13
|
Mullen KD, Sanyal AJ, Bass NM, Poordad FF,
Sheikh MY, Frederick RT, Bortey E and Forbes WP: Rifaximin is safe
and well tolerated for long-term maintenance of remission from
overt hepatic encephalopathy. Clin Gastroenterol Hepatol.
12:1390–1397.e1392. 2014. View Article : Google Scholar
|
|
14
|
de la Cabada Bauche J and Dupont HL: New
developments in traveler's diarrhea. Gastroenterol Hepatol (NY).
7:88–95. 2011.
|
|
15
|
Calanni F, Renzulli C, Barbanti M and
Viscomi GC: Rifaximin: Beyond the traditional antibiotic activity.
J Antibiot (Tokyo). 67:667–670. 2014. View Article : Google Scholar
|
|
16
|
Cheng J, Shah YM, Ma X, Pang X, Tanaka T,
Kodama T, Krausz KW and Gonzalez FJ: Therapeutic role of rifaximin
in inflammatory bowel disease: Clinical implication of human
pregnane X receptor activation. J Pharmacol Exp Ther. 335:32–41.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mencarelli A, Renga B, Palladino G,
Claudio D, Ricci P, Distrutti E, Barbanti M, Baldelli F and
Fiorucci S: Inhibition of NF-κB by a PXR-dependent pathway mediates
counter-regulatory activities of rifaximin on innate immunity in
intestinal epithelial cells. Eur J Pharmacol. 668:317–324. 2011.
View Article : Google Scholar
|
|
18
|
Kota BP, Tran VH, Allen J, Bebawy M and
Roufogalis BD: Characterization of PXR mediated P-glycoprotein
regulation in intestinal LS174T cells. Pharmacol Res. 62:426–431.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mosmann T: Rapid colorimetric assay for
cellular growth and survival: Application to proliferation and
cytotoxicity assays. J Immunol Methods. 65:55–63. 1983. View Article : Google Scholar
|
|
20
|
Renault-Mihara F, Beuvon F, Iturrioz X,
Canton B, De Bouard S, Léonard N, Mouhamad S, Sharif A, Ramos JW,
Junier MP, et al: Phosphoprotein enriched in astrocytes-15 kDa
expression inhibits astrocyte migration by a protein kinase C
delta-dependent mechanism. Mol Biol Cell. 17:5141–5152. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Guzi ska-Ustymowicz K, Pryczynicz A,
Kemona A and Czyzewska J: Correlation between proliferation
markers: PCNA, Ki-67, MCM-2 and antiapoptotic protein Bcl-2 in
colorectal cancer. Anticancer Res. 29:3049–3052. 2009.
|
|
22
|
Yang HB, Hsu PI, Chan SH, Lee JC, Shin JS
and Chow NH: Growth kinetics of colorectal adenoma-carcinoma
sequence: An immunohistochemical study of proliferating cell
nuclear antigen expression. Hum Pathol. 27:1071–1076. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cacciottolo TM, Kingdon A and Alexander
GJ: Rifaximin is largely safe and well tolerated but caution is
necessary when taken with statins. Clin Gastroenterol Hepatol.
12:17652014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cathcart J, Pulkoski-Gross A and Cao J:
Targeting matrix metalloproteinases in cancer: Bringing new life to
old ideas. Genes Dis. 2:26–34. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cheng J, Fang ZZ, Nagaoka K, Okamoto M, Qu
A, Tanaka N, Kimura S and Gonzalez FJ: Activation of intestinal
human pregnane X receptor protects against azoxymethane/dextran
sulfate sodium-induced colon cancer. J Pharmacol Exp Ther.
351:559–567. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hirota SA: Understanding the molecular
mechanisms of rifaximin in the treatment of gastrointestinal
disorders: A focus on the modulation of host tissue function. Mini
Rev Med Chem. 16:206–217. 2015. View Article : Google Scholar
|
|
27
|
Li J and Saif MW: Current use and
potential role of bevacizumab in the treatment of gastrointestinal
cancers. Biologics. 3:429–441. 2009.PubMed/NCBI
|
|
28
|
Giantonio BJ, Catalano PJ, Meropol NJ,
O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA and Benson AB III;
Eastern Cooperative Oncology Group Study E3200. Bevacizumab in
combination with oxaliplatin, fluorouracil, and leucovorin
(FOLFOX4) for previously treated metastatic colorectal cancer:
Results from the Eastern Cooperative Oncology Group Study E3200. J
Clin Oncol. 25:1539–1544. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hurwitz HI, Fehrenbacher L, Hainsworth JD,
Heim W, Berlin J, Holmgren E, Hambleton J, Novotny WF and
Kabbinavar F: Bevacizumab in combination with fluorouracil and
leucovorin: An active regimen for first-line metastatic colorectal
cancer. J Clin Oncol. 23:3502–3508. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jain RK: Normalizing tumor vasculature
with anti-angiogenic therapy: A new paradigm for combination
therapy. Nat Med. 7:987–989. 2001. View Article : Google Scholar
|
|
31
|
Huber PE, Bischof M, Jenne J, Heiland S,
Peschke P, Saffrich R, Gröne HJ, Debus J, Lipson KE and Abdollahi
A: Trimodal cancer treatment: Beneficial effects of combined
antiangiogenesis, radiation, and chemotherapy. Cancer Res.
65:3643–3655. 2005. View Article : Google Scholar : PubMed/NCBI
|
